CV Sciences Announces Publication of Two Research Studies Demonstrating the Health Benefits and Safety of Its CBD Products

CV Sciences Announces Publication of Two Research Studies Demonstrating the Health Benefits and Safety of Its CBD Products

San Diego-based CV Sciences, Inc, a prominent manufacturer and supplier and of hemp-derived cannabidiol (CBD) products, announced the publication of two research studies demonstrating the health benefits and the safety of their PlusCBD™ products in the Journal of Dietary Supplements.

The first study, “Post Marketing Safety of Plus CBD™ Products, a Full Spectrum Hemp Extract: A 2-Year Experience,” was published on May 25, 2020. This groundbreaking study adds to the growing body of literature supporting the safety of hemp-derived CBD as a dietary supplement. The study data confirms a low level of adverse effects in millions of people consuming PlusCBD™ products over a two-year period. A significant finding of the study was the absence of any reported liver toxicity, which has been detailed in some studies of high dose CBD used as a prescription drug.

Co-founder of Supplement Safety Solutions, and lead author of the study, Stephen Schmitz, MD, MPH stated, “This is the first longitudinal study of a hemp-derived cannabidiol dietary supplement being used in real-world circumstances. The study represents two years of data collected from millions of consumers using the product daily. It demonstrates that CV Sciences’ CBD products are well tolerated and safe.”

The second study, “Effects of Hemp Extract on Markers of Wellness, Stress Resilience, Recovery and Clinical Biomarkers of Safety in Overweight, But Otherwise Healthy Subjects,” published on May 27, 2020, used PlusCBD™ products to determine their benefits on mood, affect perceived recovery, stress resilience, body composition, and clinical safety markers in healthy study subjects.

Lead study author Hector L. Lopez, M.D., CSCS, FAAPMR, FISSN, observed that “In a first of its kind study, study participants consuming PlusCBD™ products had significant improvement in HDL cholesterol compared to placebo. Also, improvements in the measurement of the stress response, wellness, life pleasure, and sleep were noted. We found the products had an excellent safety profile, with no adverse signs in the liver or other biomarkers in the group taking PlusCBD™ products.”


Statements by CV Sciences President and CEO

Senior Vice President of Clinical and Regulatory Affairs for CV Sciences, Duffy MacKay, ND, stated, “These two studies add to the growing body of evidence supporting the benefits and safety of hemp-derived CBD by following participant health outcomes and experience while taking CV Sciences’ CBD products. In 2018, CV Sciences achieved self-affirmed “Generally Recognized as Safe” status resulting from our extensive non-clinical testing program. I am now proud to state that CV Sciences is the sole CBD company to have published randomized, placebo-controlled clinical trials, toxicology studies, and a systematized evaluation of post-market safety data of our CBD products.”

CV Sciences Chief Executive Officer, Joseph Dowling, said, “CV Sciences is committed to both safety and science. We work to bring high-quality, safe, and innovative products in various formulations to meet the health and wellness needs of our customers. We continually invest in clinical studies. We also aim to meet or exceed the high safety standards that both the FDA and consumers demand. We’re proud to be leaders in the CBD revolution. We strive to help the industry mature by publishing sound science. We look forward to launching innovative new products this year.”


About CV Sciences, Inc.

CV Sciences, Inc. operates in two distinct business segments; first is the company’s consumer product division, which manufactures, markets, and sells hemp-derived CBD products to a wide range of markets. The company’s second business sector is its drug development division. The drug development division focuses on the development and commercialization of CBD-based novel therapeutics.

The company’s PlusCBD™ products are sold through more than 5,700 retail locations throughout the United States. Furthermore, PlusCBD™ is the best-selling brand of hemp-derived CBD on the market today. That is according to SPINS, the leading provider of insights and syndicated data for the organic, natural, and specialty products market.

The company’s state-of-the-art facility follows all Good Manufacturing Practices and CV Sciences’ hemp products are processed, manufactured, and tested to confirm that the cannabinoid content meets the stringent company standards.

With a deep commitment to science, the health benefits of PlusCBD™ in healthy people are supported by human clinical research data. In fact, PlusCBD™ was the first CBD brand to invest in the scientific data required to receive self-affirmed Generally Recognized as Safe status.